Genetics Generation Advancement Corp.

As of June 30, 2026, Genetics Generation Advancement Corp. carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at 824.06M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Genetics Generation Advancement Corp. has 26.69M shares outstanding.

As of June 30, 2026, Genetics Generation Advancement Corp. trades at a trailing price-to-earnings ratio of 55.64. The price-to-sales ratio is 1.62, and the price-to-book ratio stands at 2.06.

As of June 30, 2026, Genetics Generation Advancement Corp. trades at an EV/EBITDA multiple of 25.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.34 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 525.55 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 824.06M versus a market cap of 1.02B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Genetics Generation Advancement Corp. maintains a current ratio of 2.50, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 25.63, indicating elevated leverage, while an interest coverage ratio of 19.26 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Genetics Generation Advancement Corp. posted a return on equity (ROE) of 3.71, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 0.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.60, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.49, useful for judging operating efficiency across full business cycles. The company generates approximately 3.75M in revenue per employee across its workforce of 163.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.45 indicates how many times Genetics Generation Advancement Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Genetics Generation Advancement Corp. recorded 1.26M in income tax expense. That works out to an effective tax rate of 6.50, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 19.38M, leaving 17.93M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Genetics Generation Advancement Corp.'s stock has declined approximately 30.10% over the past 52 weeks. The 50-day moving average sits at 38.45, while the 200-day moving average is 41.78.

Over the twelve months ended June 30, 2026, Genetics Generation Advancement Corp. generated 614.42M in revenue and converted that into 17.93M in net income, yielding earnings per share of 0.69. EBITDA reached 32.64M, while operating income came in at 2.53M.

As of June 30, 2026, Genetics Generation Advancement Corp. holds 320.81M in cash and equivalents against 126.53M in total debt, resulting in a net debt position of 17.03M. Total book value stands at 493.08M, with working capital of 310.86M providing operational flexibility.

Genetics Generation Advancement Corp. produced -475,000.00 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -39.54M in capital expenditures, free cash flow totaled -40.01M - equivalent to -1.53 per share.

Over the twelve months ended June 30, 2026, Genetics Generation Advancement Corp. posted a gross margin of 41.31, reflecting its pricing power and cost economics. The operating margin of 0.41 and net profit margin of 2.92 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -4.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.01, meaning Genetics Generation Advancement Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Genetics Generation Advancement Corp.'s most recent stock split took place on September 9, 2026 with a 1000:1049 split ratio.

As of June 30, 2026, Genetics Generation Advancement Corp. has an Altman Z-Score of 4.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.